1. Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study. (19th July 2017) Authors: Reich, K.; Pinter, A.; Lacour, J.P.; Ferrandiz, C.; Micali, G.; French, L.E.; Lomaga, M.; Dutronc, Y.; Henneges, C.; Wilhelm, S.; Hartz, S.; Paul, C. Journal: British journal of dermatology Issue: Volume 177:Number 4(2017) Page Start: 1014 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study. (1st October 2017) Authors: Reich, K.; Pinter, A.; Lacour, J.P.; Ferrandiz, C.; Micali, G.; French, L.E.; Lomaga, M.; Dutronc, Y.; Henneges, C.; Wilhelm, S.; Hartz, S.; Paul, C. Journal: British journal of dermatology Issue: Volume 177:Number 4(2017) Page Start: 1014 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. (15th February 2021) Authors: Mrowietz, U.; Warren, R.B.; Leonardi, C.L.; Saure, D.; Petto, H.; Hartz, S.; Dossenbach, M.; Reich, K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 5(2021) Page Start: 1161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0290 Effects of biologic dmards on physical function in patients with active psoriatic arthritis: results of network meta-analyses. (12th June 2018) Authors: Ruyssen-Witrand, A.; Sapin, C.; Hartz, S.; Liu Leage, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 363 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗